Uncategorized

Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch

Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch

Published

on

If the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version